Matching articles for "Oxaydo"
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • December 12, 2022; (Issue 1665)
A new CDC guideline for prescribing opioids for pain
recently became available. Nonopioid drugs for pain
were reviewed in a previous...
A new CDC guideline for prescribing opioids for pain
recently became available. Nonopioid drugs for pain
were reviewed in a previous issue.
Comparison Table: Some Oral/Transdermal Opioid Analgesics (online only)
The Medical Letter on Drugs and Therapeutics • December 12, 2022; (Issue 1665)
...
View the Comparison Table: Some Oral/Transdermal Opioid Analgesics
Roxybond - An Abuse-Deterrent Formulation of Short-Acting Oxycodone
The Medical Letter on Drugs and Therapeutics • September 10, 2018; (Issue 1555)
The FDA has approved Roxybond (Daiichi Sankyo), an
short-acting (SA) oxycodone formulation with
abuse-deterrent properties, for treatment of pain
requiring management with an opioid. Roxybond
is the first...
The FDA has approved Roxybond (Daiichi Sankyo), an
short-acting (SA) oxycodone formulation with
abuse-deterrent properties, for treatment of pain
requiring management with an opioid. Roxybond
is the first SA opioid to be approved as an abuse-deterrent
product. Oxaydo, another IR oxycodone
formulation, has properties that discourage its
intranasal and intravenous use, but is not considered
an abuse-deterrent product by the FDA. Use of
opioids for treatment of pain was reviewed in a
recent issue.
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • April 9, 2018; (Issue 1544)
Use of nonopioid drugs for pain was reviewed in a
previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations...
Use of nonopioid drugs for pain was reviewed in a
previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations of full opioid agonists should generally be used for acute pain that is severe enough to require treatment with an opioid. Use of extended-release or long-acting opioid formulations initially and treatment durations >1 week have been associated with an increased risk of unintended long-term use.
Comparison Table: Some Oral/Topical Opioid Analgesics (online only)
The Medical Letter on Drugs and Therapeutics • April 9, 2018; (Issue 1544)
...
View the Comparison Table: Some Oral/Topical Opioid Analgesics
Abuse-Deterrent Opioids
The Medical Letter on Drugs and Therapeutics • June 5, 2017; (Issue 1522)
Development of abuse-deterrent opioid products,
including reformulation of existing products, has
become a priority for drug manufacturers and
public health advocates. Since our last article on
this...
Development of abuse-deterrent opioid products,
including reformulation of existing products, has
become a priority for drug manufacturers and
public health advocates. Since our last article on
this subject, several new abuse-deterrent opioid
formulations have been approved by the FDA,
including an oxycodone tablet formulation (Roxybond
– Inspirion) that is the first immediate-release opioid
product FDA-approved to include claims of abuse
deterrence in its labeling. No opioid formulation
prevents consumption of a large number of intact
dosage units, the most common method of abuse.
Abuse-deterrent formulations have one or more
properties that make their intentional nontherapeutic
use more difficult, less attractive, or less rewarding.
Arymo ER - A New Abuse-Deterrent Morphine Formulation
The Medical Letter on Drugs and Therapeutics • April 24, 2017; (Issue 1519)
The FDA has approved Arymo ER (Egalet), a new
extended-release, abuse-deterrent tablet formulation
of morphine sulfate, for management of pain severe
enough to require daily, around-the-clock,...
The FDA has approved Arymo ER (Egalet), a new
extended-release, abuse-deterrent tablet formulation
of morphine sulfate, for management of pain severe
enough to require daily, around-the-clock, long-term
opioid treatment and for which alternative treatment
options are inadequate. Arymo ER can only be
marketed to deter abuse by injection because another
single-entity, extended-release morphine product,
MorphaBond, which has not been marketed to date,
has marketing exclusivity for deterrence of abuse by
the intranasal route through October 2018.